Bristol's Osborne Clarke advises on Torbay Pharmaceuticals transaction
Devon-based Torbay Pharmaceuticals has been sold to private equity firm NorthEdge, with the former being advised by Bristol law firm Osborne Clarke.
NorthEdge acquired the Paignton-headquartered firm, which supplies healthcare and medical organisations throughout the UK and internationally, from the Torbay and Devon NHS Foundation Trust.
READ MORE: Bristol-based Osborne Clarke recognised as the UK's leading law firm
Torbay Pharma employs 250 staff and over the last six years has seen rapid growth that has resulted in increasing demand for its commercial-scale sterile injectable fill/finish capabilities.
NorthEdge’s investment will see Torbay strengthen its capabilities and significantly expand its reach in North America, while continuing to grow and invest in its team to enable greater automation of inspection and packaging processes and strengthen its plastic vial capabilities, said the law firm.
NorthEdge backs entrepreneurial and ambitious management teams in the technology, healthcare, business services and specialised industrials sectors.
"Osborne Clarke delivered a sense of calm throughout the transaction," said Emma Rooth, CEO of Torbay Pharmaceuticals.
"We were provided with clear explanations free of legal jargon and hand holding when necessary. We felt like we were working with advisors who understood the key issues and always found the right solutions."
The Osborne Clarke team was led by partner Alisdair Livingstone, assisted by associate director Seamus McKimm and associate Matt Mayes.
Associate director Nicholas Haywood advised on employment and partner David Nisbet & senior associate Bridget Baillie advised on tax.
Osborne Clarke says it's a go-to practice for companies in the pharmaceutical and life sciences sector.
The team advises across all corporate issues, from equity and debt fundraisings to M&A, IPOs and JVs.
Visit Hampshire Biz News for bright, upbeat and positive business news from the county
